Lisata Therapeutics, Inc. (LSTA)
| Market Cap | 9.73M -58.2% |
| Revenue (ttm) | 100,000 -90.7% |
| Net Income | -14.62M |
| EPS | -1.64 |
| Shares Out | 9.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,212 |
| Open | 1.078 |
| Previous Close | 1.080 |
| Day's Range | 1.077 - 1.169 |
| 52-Week Range | 0.988 - 5.070 |
| Beta | 0.88 |
| Analysts | Hold |
| Price Target | 4.00 (+270.37%) |
| Earnings Date | Aug 6, 2026 |
About LSTA
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as C... [Read more]
Financial Performance
In 2025, Lisata Therapeutics's revenue was $170,000, a decrease of -83.00% compared to the previous year's $1.00 million. Losses were -$16.59 million, -17.01% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LSTA stock is "Hold." The 12-month stock price target is $4.0, which is an increase of 270.37% from the latest price.
News
Lisata Therapeutics Quarterly report: Q2 2026
Lisata Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Lisata Therapeutics provides update following termination of Kuva Labs merger
Lisata Therapeutics (LSTA) provided an update following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp. The company said, “Lisata has filed suit in…
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders
Lisata Therapeutics terminates merger with Kuva Labs
In a regulatory filing on Friday, Lisata Therapeutics (LSTA) disclosed that on July 24, the company terminated the previously announced agreement and plan of merger, dated as of March 6,…
Lisata Therapeutics downgraded to Hold from Buy at Brookline
Brookline downgraded Lisata Therapeutics (LSTA) to Hold from Buy after the Kuva Labs deal collapsed.
Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ: LSTA) on behalf of investors who suffered losses and whether those losses may be r...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 15, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lisata Therapeutics, I...
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up t...
Lisata Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Lisata Therapeutics (LSTA) to Neutral from Buy without a price target Risk of the Kuva Labs takeover deal not closing has increased, the analyst tells investors in…
Lisata Therapeutics Quarterly report: Q1 2026
Lisata Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Lisata Therapeutics Annual report: Q4 2025
Lisata Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Lisata Therapeutics to be acquired by Kuva Labs for $5 per share cash plus CVR
Lisata Therapeutics (LSTA) announced that it has entered into a definitive agreement to be acquired by Kuva Labs, a privately-held company. Under the terms of the merger agreement, Kuva will…
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share
Lisata Therapeutics announces mutual termination of license agreement with Qilu
Lisata Therapeutics (LSTA) has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical. The original agreement, negotiated and implemented with CEN...
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region
Lisata Therapeutics downgraded to Hold from Buy at Brookline
Brookline analyst Kemp Dolliver downgraded Lisata Therapeutics (LSTA) to Hold from Buy after the company entered into a binding term sheet to be acquired by Kuva Labs for $4.00 per…
Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share
Lisata Therapeutics (LSTA) entered into a binding term sheet to be acquired by Kuva Labs. Pursuant to the terms and conditions of the term sheet, Kuva and Lisata agreed to…
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium ove...
Lisata Therapeutics Earnings Call Transcript: Q3 2025
Certepetide development advanced with positive clinical data across multiple cancer trials and new strategic partnerships. Operating expenses and net loss decreased year-over-year, with a cash runway into Q1 2027, excluding phase III costs. Final pivotal trial data and further business milestones are expected in 2026.
Lisata Therapeutics Quarterly report: Q3 2025
Lisata Therapeutics has published its Q3 2025 quarterly earnings report on November 6, 2025.
Lisata Therapeutics Earnings release: Q3 2025
Lisata Therapeutics released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Dr...
Lisata Therapeutics Slides: Corporate Presentation
Lisata Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2025.
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'
BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...